Lesser DLL4 expression was observed in the vasculature of mJAG1-tumours compared to mDLL4-tumours when treated with bevacizumab (IX versus VIII) as well as treated with the combination of DBZ and bevacizumab (XII versus XI) but more DLL4 expression occurred in the vasculature of mJAG1-tumour than in EV-tumours when treated with the combination (XII versus X). This evidence concerns the gene DLL4 and neoplasm.